GTx, Inc. GTXI announced the presentation today of results of a preclinical study demonstrating that Capesaris treatment achieved and maintained castration over the entire 9 month study without evidence of gynecomastia in male cynomolgus monkeys.
The data were presented at the Annual Meeting of the American Urological Association.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in